Glenmark, a name in pharma is a stock to watch for by the seasoned investors with term investment. An investment grade stock, it has a very respectable price to earning at 12 against the industry price to earning of 30. Good BV at 175 and dividend of 200% with FV of Rs.1/-, it is a debt free company with EPS of around 57 . Small equity capital of Rs.27 crore, it has massive reserves of Rs.4924 (Mar 15) having seen a quantum jump. For Mar 2015 it clocked good valuations ith ROE of 26%.
India Inc as a whole, could not post good results for the QE Sept 2015 and similar was the case with Glenmark. Its sales and net profit had been down. But, with management of Glenmark adding new product to its inventory for dermitology, diabetes, cardiology and respiratory, its target the domestic market more aggressively.
One should keep a close eye on this stock for reasonable return.